课题基金 / 基金详情

MOLECULAR NEUROBIOLOGY OF DEPRESSION

MOLECULAR NEUROBIOLOGY OF DEPRESSION
抑郁症的分子神经生物学
批准号:
6391435
负责人:
Richard Charles Shelton
金额:
$10.63万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-08-01 至 2004-07-31

项目摘要

项目成果

Richard Charles Shelton的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a request for five years of salary support via the Midcareer Investigator Award in Patient-Oriented Research (K24). Throughout my career I have sought to bridge basic neurobiological and clinical domains, with special emphasis on mood disorders. By the early 1990's, I began to redirect my energies toward the development of a series of studies using newer molecular biological methods to investigate the causes and possible treatments for depression. Using a fibroblast cell culture model, my collaborators and I have discovered that melancholic major depressives have a reduction of cyclic AMP binding to the regulatory subunit of protein kinase A (PKA) linked to beta adrenoceptors. This results in a concomitant reduction in phosphorylation activity (including that of CREB) and altered gene expression. We also have shown an altered expression of a specific nuclear phosphatase gene using the differential display reverse transcription polymerase chain reaction methodology with cPCR. Herein, I have outlined these findings along with plans for related projects over the next five years. I also have described briefly two other project areas that stand in the mid-ground between basic and clinical investigations. One is an investigation of mood regulation using new clinical ratings instruments (developed, in part by our research group) to measure components of mood under conditions of pharmacological manipulation. The second represents a novel therapeutic intervention in refractory major depression. Drawing from a set of basic laboratory observations, I have conducted a successful trial of the combination of olanzapine and fluoxetine in refractory depressives. Together, these study areas demonstrate my capacity to bridge from basic laboratory findings, on the one hand, to clinical phenomenology and treatment, on the other. Finally, consistent with the goals of the K24, I have a long track-record of mentorship of new investigators from a number of disciplines. However, an increasing burden of administrative and clinical responsibilities threatens my research productivity and mentorship. This award will relieve me of many of these demands and will allow me to: 1.Develop further expertise in basic molecular biological methods; 2. Develop new projects oriented to future funding opportunities; and 3. Continue to mentor the next generation of investigators.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
  • 批准号:
    7857927
  • 项目类别:
  • 资助金额:
    $34.58万
  • 财政年份:
    2008
  • 负责人:
    Richard Charles Shelton
  • 依托单位:
2/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
  • 批准号:
    7613470
  • 项目类别:
  • 资助金额:
    $34.58万
  • 财政年份:
    2008
  • 负责人:
    Richard Charles Shelton
  • 依托单位:
2/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
2/2-Ziprasidone Augmentation of SSRIs for Treatment-Resistant Depression (TRD)
  • 批准号:
    8050168
  • 项目类别:
  • 资助金额:
    $34.24万
  • 财政年份:
    2008
  • 负责人:
    Richard Charles Shelton
  • 依托单位:
海外基金